Sclerosing cholangitis

Current Opinion in Gastroenterology

Volumn 23, Issue 3, 2007, Pages 310-316

  Maggs, James R L ^a   Chapman, Roger W ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Cholangiocarcinoma; Orthotopic liver transplantation; Primary sclerosing cholangitis; Ursodeoxycholic acid

Indexed keywords

24 NORURSODEOXYCHOLIC ACID; BEZAFIBRATE; CHEMOKINE RECEPTOR CCR5; FLUOROPYRIMIDINE; IMMUNOGLOBULIN G4; INTERCELLULAR ADHESION MOLECULE 1; PENICILLAMINE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID DERIVATIVE;

AUTOIMMUNE PANCREATITIS; BILE DUCT CARCINOMA; BILIARY TRACT ENDOSCOPY; CHEMOTHERAPY INDUCED CHOLANGITIS; COLORECTAL CANCER; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; ELASTOGRAPHY; ENTERITIS; GASTROINTESTINAL ENDOSCOPY; GENE MUTATION; HUMAN; HYPERLIPIDEMIA; LITHOTRIPSY; LIVER TRANSPLANTATION; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; METASTASIS; NONHUMAN; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; RISK FACTOR; SCLEROSING CHOLANGITIS; SECONDARY SCLEROSING CHOLANGITIS; ULCERATIVE COLITIS;

CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLANGITIS, SCLEROSING; HUMANS; LIVER TRANSPLANTATION; MORBIDITY; PROGNOSIS; WORLD HEALTH;

EID: 34147167211     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32805867e6     Document Type: Review

References (52)

1. Worthington J, Chapman R. Primary sclerosing cholangitis. Orphanet J Rare Dis 2006; 1:41.
2. Melum E, Karlsen TH, Broome U, et al. The 32-base pair deletion of the chemokine receptor 5 gene (CCR5-Delta32) is not associated with primary sclerosing cholangitis in 363 Scandinavian patients. Tissue Antigens 2006; 68:78-81.
3. Henckaerts L, Fevery J, Van Steenbergen W, et al. CC-type chemokine receptor 5-Delta32 mutation protects against primary sclerosing cholangitis. Inflamm Bowel Dis 2006; 12:272-277.
4. Wiencke K, Boberg KM, Donaldson P, et al. No major effect of the CD28/CTLA4/ICOS gene region on susceptibility to primary sclerosing cholangitis. Scand J Gastroenterol 2006; 41:586-591.
5. Yang X, Cullen SN, Li JH, et al. Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of intercellular adhesion molecule-1. J Hepatol 2004; 40:375-379.
6. Bowlus CL, Karlsen TH, Broome U, et al. Analysis of MAdCAM-1 and ICAM-1 polymorphisms in 365 Scandinavian patients with primary sclerosing cholangitis. J Hepatol 2006; 45:704-710.
7. Karlsen TH, Hampe J, Wiencke K, et al. Genetic polymorphisms associated with inflammatory bowel disease do not confer risk for primary sclerosing cholangitis. Am J Gastroenterol 2006; 13 November [Epub ahead of print]. • Common IBD-associated gene polymorphisms do not confer any susceptibility to PSC.
8. Karlsen TH, Lie BA, Frey Froslie K, et al. Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis. Gastroenterology 2006; 131:781-787. • This important study demonstrated that SXR gene polymorphisms may influence disease severity but not susceptibility.
9. Eksteen B, Miles A, Curbishley SM, et al. Epithelial inflammation is associated with CCL28 production and the recruitment of regulatory T cells expressing CCR10. J Immunol 2006; 177:593-603.
10. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 2006; 6:244-251.
11. Popov Y, Patsenker E, Fickert P, et al. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol 2005; 4:1045-1054.
12. O'Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 2006; 26:3-21. •A comprehensive review of the etiopathogenesis of PSC.
13. Moritoki Y, Lian ZX, Ohsugi Y, et al. B cells and autoimmune liver diseases. Autoimmun Rev 2006; 5:449-457.
14. Bergquist A, Montgomery SM, Lund U, et al. Perinatal events and the risk of developing primary sclerosing cholangitis. World J Gastroenterol 2007; 12:6037-6040.
15. Tischendorf JJ, Hecker H, Kruger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2006; 13 October [Epub ahead of print].
16. Bergquist A, Glaumann H, Lindberg B, Broome U. Primary sclerosing cholangitis can present with acute liver failure: report of two cases. J Hepatol 2006; 44:1005-1008.
17. Levy C, Lindor KD. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin Liver Dis 2006; 26:22-30.
18. Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006; 101:2070-2075.
19. Hirano K, Kawabe T, Yamamoto N, et al. Serum IgG4 concentrations in pancreatic and biliary diseases. Clin Chim Acta 2006; 367:181-184.
20. van Buuren HR, Vleggaar FP, Willemien Erkelens G, et al. Autoimmune pancreatocholangitis: a series of ten patients. Scand J Gastroenterol Suppl 2006; (243):70-78.
21. Kulaksiz H, Rudolph G, Kloeters-Plachky P, et al. Biliary candida infections in primary sclerosing cholangitis. J Hepatol 2006; 45:711-716.
22. Pohl J, Ring A, Stremmel W, Stiehl A. The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2006; 18:69-74.
23. Abdalian R, Heathcote EJ. Sclerosing cholangitis: a focus on secondary causes. Hepatology 2006; 44:1063-1074. •• An excellent and detailed review on the secondary causes of sclerosing cholangitis.
24. Deltenre P, Valla DC. Ischemic cholangiopathy. J Hepatol 2006; 44:806-817.
25. Hoffmeister B, Ockenga J, Schachschal G, et al. Rapid development of secondary sclerosing cholangitis due to vancomycin-resistant enterococci. J Infect 2006; 13 October [Epub ahead of print].
26. Jaeger C, Mayer G, Henrich R, et al. Secondary sclerosing cholangitis after long-term treatment in an intensive care unit: clinical presentation, endoscopic findings, treatment, and follow-up. Endoscopy 2006; 38:730-734.
27. Sandrasegaran K, Alazmi WM, Tann M, et al. Chemotherapy-induced sclerosing cholangitis. Clin Radiol 2006; 61:670-678.
28. Alazmi WM, McHenry L, Watkins JL, et al. Chemotherapy-induced sclerosing cholangitis: long-term response to endoscopic therapy. J Clin Gastroenterol 2006; 40:353-357.
29. Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006; 130:1941-1949. • This study investigates risk factors for colorectal cancer in ulcerative colitis patients concluding that PSC does not confer any increase in risk contrary to previous data.
30. Wolf JM, Rybicki LA, Lashner BA. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005; 22:783-788.
31. Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A. Effect of colitis and ileoanal pouch on biliary enrichment of ursodeoxycholic acid in primary sclerosing cholangitis. Dig Dis Sci 2006; 51:618-622.
32. Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006; 26:31-41.
33. Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis 2006; 26:42-51.
34. Moreno Luna LE, Gores GJ. Advances in the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver Transpl 2006; 12:S15-S19.
35. Tischendorf JJ, Meier PN, Strassburg CP, et al. Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2006; 41:1227-1234.
36. Moff SL, Clark DP, Maitra A, et al. Utility of bile duct brushings for the early detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Clin Gastroenterol 2006; 40:336-341.
37. Boberg KM, Jebsen P, Clausen OP, et al. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2006; 45:568-574.
38. Tischendorf JJ, Kruger M, Trautwein C, et al. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy 2006; 38:665-669.
39. Awadallah NS, Chen YK, Piraka C, et al. Is there a role for cholangioscopy in patients with primary sclerosing cholangitis? Am J Gastroenterol 2006; 101:284-291.
40. Stiehl A. Primary sclerosing cholangitis: the role of endoscopic therapy. Semin Liver Dis 2006; 26:62-68.
41. Moff SL, Kamel IR, Eustace J, et al. Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc 2006; 64:219-223.
42. Berstad AE, Aabakken L, Smith HJ, et al. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2006; 4:514-520.
43. Mesenas S, Vu C, Doig L, Meenan J. Duodenal EUS to identify thickening of the extrahepatic biliary tree wall in primary sclerosing cholangitis. Gastrointest Endosc 2006; 63:403-408.
44. Corpechot C, El Naggar A, Poujol-Robert A, et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006; 43:1118-1124. • This study validates the use of transient elastography in patients with cholestatic liver disease.
45. Cullen SN, Chapman RW. The medical management of primary sclerosing cholangitis. Semin Liver Dis 2006; 26:52-61.
46. Fickert P, Wagner M, Marschall HU, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006; 130:465-481. •• This interesting study demonstrates that norUDCA has superior efficacy in comparison to UDCA in an animal model of sclerosing cholangitis.
47. Kita R, Takamatsu S, Kimura T, et al. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol 2006; 41:686-692.
48. Klingenberg SL, Chen W. D-Penicillamine for primary sclerosing cholangitis. Cochrane Database Syst Rev 2006:CD004182.
49. Bjøro K, Brandsaeter B, Foss A, Schrumpf E. Liver transplantation in primary sclerosing cholangitis. Semin Liver Dis 2006; 26:69-79.
50. Gordon F. Recurrent primary sclerosing cholangitis: clinical diagnosis and long-term management issues. Liver Transpl 2006; 12:S73-S75.
51. Futagawa Y, Waki K, Cai J. The association of HLA-DR13 with lower graft survival rates in hepatitis B and primary sclerosing cholangitis Caucasian patients receiving a liver transplant. Liver Transpl 2006; 12:600-604.
52. Schmitz V, Neumann UP, Puhl G, et al. Surgical complications and long-term outcome of different biliary reconstructions in liver transplantation for primary sclerosing cholangitis-choledochoduodenostomy versus choledochojejunostomy. Am J Transplant 2006; 6:379-385.